Vertex Pharmaceuticals, Inc.

Repare Therapeutics Inc.

Janek Szychowski

Claudio F Sturino

Tiansheng Wang

Francois Maltais

Jingrong Cao

Brian Ledford

Jon H Come

Suganthini S Nanthakumar

Bingcan Liu

Warren A Dorsch

Elaine B Krueger

Leslie A Dakin

Timothy J Senter

Anne Fortier

Olivier Nicolas

Camil Sayegh

Lee Fader

Francois Denis

Martine Hamel

Luc J Farmer

Yeeman K Ramtohul

Constantin G Yannopoulos

Evelyne Dietrich

Vouy Linh Truong

Monica Bubenik

Frederic Vallee

Julien Martel

Jean-Eric Lacoste

Stephanie Lessard

Jean-François Truchon

Sheldon N Crane

Miguel St-Onge

Robert Papp

Camil Elie Sayegh

Kaveh Matinkhoo

Stephane Dorich

Stephanie Dorich

Pierre-Andre Fournier

Alexander Perryman

Frédéric Vallée

Patrick Beaulieu

Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use

The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

Inhibitors of APOL1 and methods of using same

The disclosure provides at least one entity chosen from compounds of Formula (I)

The present invention relates to compounds useful as inhibitors of the PAR-2 signaling pathway. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of GPCRs in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such GPCRs; and the comparative evaluation of new inhibitors of the PAR-2 signaling pathway. The compounds of this invention have formula I: wherein the variables are as defined herein.

Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway

Growing community of inventors

Montreal, Canada

Janek Szychowski